Report : North America Liver Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type (Laboratory Tests, Endoscopy, Imaging, Biopsy, and Others) and End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, and CRO Laboratories)
Laboratory tests segment to dominate the North America Liver Cancer Diagnostics Market during 2021–2028
According to a new market research study on “North America Liver Cancer Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type and End User” is expected to reach US$ 6,666.24 million by 2028 from US$ 3,843.93 million in 2021. The market is estimated to grow at a CAGR of 8.2% from 2021 to 2028. The report provides trends prevailing in the North America liver cancer diagnostics market along with the drivers and restraints pertaining to the market growth. Strengthening R&D investments for the development of novel diagnostic testing, growing prevalence of liver cancer, and prospering emergence of new technologies are the major factor driving the growth of the North America liver cancer diagnostics market. However, higher cost of technologically advanced liver cancer diagnostic solutions hinders the growth of North America liver cancer diagnostics market.
The North America liver cancer diagnostics market is segmented on the basis of type, end user, and country. Based on type, the market is segmented into laboratory tests, imaging, endoscopy, biopsy, and others. In 2021, the laboratory tests segment held a larger share of the market; and the imaging segment is expected to register a higher CAGR during the forecast period. Further based on laboratory tests, the North America liver cancer diagnostics market is segmented into blood tests and biomarkers. In 2021, the blood tests segment held the largest market share; and the same segment is expected to register the highest CAGR in the market during the forecast period. Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. In 2021, the hospitals and diagnostic laboratories segment held a larger share of the market; and the same segment is expected to register a higher CAGR during the forecast period. Further, based on country, the North America liver cancer diagnostics market is segmented into the US, Canada, and Mexico. In 2021, the US held the largest market share; and it is also expected to grow at the fastest CAGR during the forecast period.
Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; and Helio, Inc. are among the leading companies in the North America liver cancer diagnostics market. For instance, Helio, Inc and its commercial partner, Fulgent Genetics, Inc. commercially launched HelioLiver, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. The test detect HCC at its earliest stages thus, providing potential to enable more curative treatment options.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com